학술논문
Pre-emptive treatment of heart failure exacerbations in patients managed with the HeartLogic™ algorithm.
Document Type
Academic Journal
Author
Garcia R; Department of Cardiology, University Hospital of Poitiers, Poitiers, France.; Centre d'investigation clinique 1402, University Hospital of Poitiers, Poitiers, France.; Gras D; Department of Cardiology, Hôpital privé du Confluent, Nantes, France.; Mansourati J; Department of Cardiology, University Hospital of Brest, Brest, France.; Defaye P; Department of Cardiology, University Hospital Grenoble Alpes, Grenoble, France.; Bisson A; Department of Cardiology, University Hospital of Tours, Chambray-lès-Tours, France.; Department of Cardiology, University Hospital of Orléans, Orléans, France.; Boveda S; Department of Cardiology, Clinique Pasteur, Toulouse, France.; Universiteit Ziekenhuis, Vrije Universiteit Brussel (VUB), Jette, Belgium.; Gandjbakhch E; Department of Cardiology, Hôpital la Pitié Salpétrière, Paris, France.; Gras M; Department of Cardiology, University Hospital of Poitiers, Poitiers, France.; Gueffet JP; Department of Cardiology, Hôpital privé du Confluent, Nantes, France.; Himbert C; Department of Cardiology, Hôpital la Pitié Salpétrière, Paris, France.; Jacon P; Department of Cardiology, University Hospital Grenoble Alpes, Grenoble, France.; Khattar P; Department of Cardiology, Hospital of Lorient, Lorient, France.; Lequeux B; Department of Cardiology, University Hospital of Poitiers, Poitiers, France.; Li A; Department of Cardiology, St. George's University of London, Cranmer Terrace, London, UK.; Mansourati V; Department of Cardiology, University Hospital of Brest, Brest, France.; Minois D; Department of Cardiology, University Hospital of Nantes, Nantes Cedex 1, France.; Marijon E; Department of Cardiology, Hôpital Européen Georges Pomipdou, Paris, France.; Paris-Sudden Death Expertise Center (Paris-SDEC), Paris, France.; Pierre B; Department of Cardiology, University Hospital of Tours, Chambray-lès-Tours, France.; Probst V; Department of Cardiology, University Hospital of Nantes, Nantes Cedex 1, France.; Degand B; Department of Cardiology, University Hospital of Poitiers, Poitiers, France.
Source
Publisher: John Wiley & Sons Ltd on behalf of the European Society of Cardiology Country of Publication: England NLM ID: 101669191 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2055-5822 (Electronic) Linking ISSN: 20555822 NLM ISO Abbreviation: ESC Heart Fail Subsets: MEDLINE
Subject
Language
English
Abstract
Aims: Heart failure (HF) is a chronic disease affecting 64 million people worldwide and places a severe burden on society because of its mortality, numerous re-hospitalizations and associated costs. HeartLogic™ is an algorithm programmed into implanted devices incorporating several biometric parameters which aims to predict HF episodes. It provides an index which can be monitored remotely, allowing pre-emptive treatment of congestion to prevent acute decompensation. We aim to assess the impact and security of pre-emptive HF management, guided by the HeartLogic™ index.
Methods and Results: The HeartLogic™ France Cohort Study is an investigator-initiated, prospective, multi-centre, non-randomized study. Three hundred ten patients with a history of HF (left ventricular ejection fraction ≤40%; or at least one episode of clinical HF with elevated NT-proBNP ≥450 ng/L) and implanted with a cardioverter defibrillator enabling HeartLogic™ index calculation will be included across 10 French centres. The HeartLogic™ index will be monitored remotely for 12 months and in the event of a HeartLogic™ index ≥16, the local investigator will contact the patient for assessment and adjust HF treatment as necessary. The primary endpoint is unscheduled hospitalization for HF. Secondary endpoints are all-cause mortality, cardiovascular death, HF-related death, unscheduled hospitalizations for ventricular or atrial arrhythmia and HeartLogic™ index evolution over time. Blood samples will be collected for biobanking, and quality of life will be assessed. Finally, the safety of a HeartLogic™-triggered strategy for initiating or increasing diuretic therapy will be assessed. A blind and independent committee will adjudicate the events.
Conclusions: The HeartLogic™ France Cohort Study will provide robust real-world data in a cohort of HF patients managed with the HeartLogic™ algorithm allowing pre-emptive treatment of heart failure exacerbations.
(© 2024 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.)
Methods and Results: The HeartLogic™ France Cohort Study is an investigator-initiated, prospective, multi-centre, non-randomized study. Three hundred ten patients with a history of HF (left ventricular ejection fraction ≤40%; or at least one episode of clinical HF with elevated NT-proBNP ≥450 ng/L) and implanted with a cardioverter defibrillator enabling HeartLogic™ index calculation will be included across 10 French centres. The HeartLogic™ index will be monitored remotely for 12 months and in the event of a HeartLogic™ index ≥16, the local investigator will contact the patient for assessment and adjust HF treatment as necessary. The primary endpoint is unscheduled hospitalization for HF. Secondary endpoints are all-cause mortality, cardiovascular death, HF-related death, unscheduled hospitalizations for ventricular or atrial arrhythmia and HeartLogic™ index evolution over time. Blood samples will be collected for biobanking, and quality of life will be assessed. Finally, the safety of a HeartLogic™-triggered strategy for initiating or increasing diuretic therapy will be assessed. A blind and independent committee will adjudicate the events.
Conclusions: The HeartLogic™ France Cohort Study will provide robust real-world data in a cohort of HF patients managed with the HeartLogic™ algorithm allowing pre-emptive treatment of heart failure exacerbations.
(© 2024 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.)